PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- SAGA Diagnostics® Launches Ultrasensitive Pathlight™ MRD Test in Colorectal Cancer (Business Wire)
- Task force updates ERCP quality metrics (GI & Hepatology News)
- New simulator mimics real tissue for safer endoscopic cancer surgery training (Medical Xpress)
- 5 GI leaders on what’s changing in colonoscopy (Becker’s GI & Endoscopy)
- Scientists create a luminous pill with biosensors meant to replace colonoscopies (Earth.com)
- FUJIFILM 800 Series Duodenoscopes Now Compatible with CE Mark Approved ULTRA GI Cycle (Fujifilm)
- Private Equity’s Healthcare Boom Is Getting More Crowded (MedCity News)
- Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab (Reuters)
